Hydroxamic acid derivatives as inhibitors of cytokine production
US5821262A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 28, 1996 |
| Grant date | Oct 13, 1998 |
| Priority date | — |
| Expiry date | Oct 28, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C323/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula (I): ##STR1## wherein: R.sup.1 represents a (C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, or heterocyclyl group; R.sup.2 represents a (C.sub.1 -C.sub.6)alkyl group; R.sup.3 represents: PA2 (I) the side chain of arginine, lysine, tryptophan, histidine, serine, threonine, or cysteine, in which any polar amino, hydroxy, mercapto, guanidyl, imidazolyl or indolyl group is rendered substantially non-polar by substitution at the polar N-, O- or S-atom; or PA2 (ii) the side chain of aspartic or glutamic acid, in which side chain the carboxylic acid group is amidated; PA1 R.sup.4 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl or phenyl (C.sub.1 -C.sub.6)alkyl group; R.sup.5 represents hydrogen or and n is 0, 1 or 2; or substituted phenyl groups; or a salt solvate or hydrate thereof. Compositions containing compound (I) and methods for treatment of diseases or conditions mediated by TNF or MMPs in mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.